Jeff Johnson
Stock Analyst at Baird
(4.69)
# 170
Out of 4,893 analysts
143
Total ratings
60.2%
Success rate
30.56%
Average return
Main Sectors:
Stocks Rated by Jeff Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Maintains: Outperform | $107 → $97 | $74.95 | +29.42% | 17 | May 30, 2025 | |
| NVST Envista Holdings | Upgrades: Outperform | $21 → $23 | $20.38 | +12.86% | 10 | May 27, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $130 → $115 | $95.20 | +20.80% | 14 | May 6, 2025 | |
| DXCM DexCom | Maintains: Outperform | $115 → $105 | $84.87 | +23.72% | 14 | May 2, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $33 → $24 | $15.85 | +51.42% | 16 | May 1, 2025 | |
| ALC Alcon | Maintains: Outperform | $104 → $108 | $86.98 | +24.17% | 9 | Feb 27, 2025 | |
| BBNX Beta Bionics | Initiates: Neutral | $20 | $13.28 | +50.60% | 1 | Feb 20, 2025 | |
| SYK Stryker | Maintains: Outperform | $378 → $405 | $392.05 | +3.30% | 11 | Oct 30, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $325 → $276 | $200.48 | +37.67% | 18 | Oct 24, 2024 | |
| HSIC Henry Schein | Maintains: Outperform | $92 → $82 | $74.14 | +10.60% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 → $238 | $297.46 | -19.99% | 12 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $70 | $35.56 | +96.85% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $61 | $15.23 | +300.53% | 4 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $67 | $16.57 | +304.35% | 6 | Feb 18, 2022 |
The Cooper Companies
May 30, 2025
Maintains: Outperform
Price Target: $107 → $97
Current: $74.95
Upside: +29.42%
Envista Holdings
May 27, 2025
Upgrades: Outperform
Price Target: $21 → $23
Current: $20.38
Upside: +12.86%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Outperform
Price Target: $130 → $115
Current: $95.20
Upside: +20.80%
DexCom
May 2, 2025
Maintains: Outperform
Price Target: $115 → $105
Current: $84.87
Upside: +23.72%
Tandem Diabetes Care
May 1, 2025
Maintains: Neutral
Price Target: $33 → $24
Current: $15.85
Upside: +51.42%
Alcon
Feb 27, 2025
Maintains: Outperform
Price Target: $104 → $108
Current: $86.98
Upside: +24.17%
Beta Bionics
Feb 20, 2025
Initiates: Neutral
Price Target: $20
Current: $13.28
Upside: +50.60%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378 → $405
Current: $392.05
Upside: +3.30%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $325 → $276
Current: $200.48
Upside: +37.67%
Henry Schein
Aug 7, 2024
Maintains: Outperform
Price Target: $92 → $82
Current: $74.14
Upside: +10.60%
Dec 21, 2023
Upgrades: Outperform
Price Target: $180 → $238
Current: $297.46
Upside: -19.99%
Aug 4, 2023
Maintains: Outperform
Price Target: $67 → $70
Current: $35.56
Upside: +96.85%
Jul 28, 2023
Maintains: Outperform
Price Target: $53 → $61
Current: $15.23
Upside: +300.53%
Feb 18, 2022
Maintains: Outperform
Price Target: $78 → $67
Current: $16.57
Upside: +304.35%